Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 1,523 Shares

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,523 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $91.38, for a total value of $139,171.74. Following the transaction, the chief financial officer now directly owns 73,039 shares in the company, valued at $6,674,303.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, April 2nd, Michael Burkes Brophy sold 1,378 shares of Natera stock. The shares were sold at an average price of $92.62, for a total value of $127,630.36.
• On Thursday, March 28th, Michael Burkes Brophy sold 914 shares of Natera stock. The shares were sold at an average price of $90.42, for a total value of $82,643.88.
• On Tuesday, March 5th, Michael Burkes Brophy sold 2,826 shares of Natera stock. The shares were sold at an average price of $88.36, for a total value of $249,705.36.
• On Tuesday, February 6th, Michael Burkes Brophy sold 34,029 shares of Natera stock. The shares were sold at an average price of $70.03, for a total value of $2,383,050.87.
• On Thursday, February 1st, Michael Burkes Brophy sold 22,281 shares of Natera stock. The shares were sold at an average price of $67.73, for a total value of $1,509,092.13.
• On Monday, January 29th, Michael Burkes Brophy sold 3,235 shares of Natera stock. The stock was sold at an average price of $65.09, for a total value of $210,566.15.

Natera Trading Up 2.7 %

Shares of NTRA opened at $91.04 on Wednesday. The business’s 50-day moving average price is $86.40 and its 200 day moving average price is $66.49. The stock has a market capitalization of $10.99 billion, a P/E ratio of -24.02 and a beta of 1.37. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $98.82. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The firm had revenue of $311.11 million during the quarter, compared to analyst estimates of $300.38 million. Analysts expect that Natera, Inc. will post -2.35 earnings per share for the current year.

Institutional Investors Weigh In On Natera

A number of institutional investors have recently bought and sold shares of NTRA. National Bank of Canada FI acquired a new stake in Natera during the 3rd quarter worth about $1,932,000. CWM LLC boosted its position in Natera by 224.4% during the 3rd quarter. CWM LLC now owns 1,317 shares of the medical research company’s stock worth $58,000 after acquiring an additional 911 shares during the period. SG Americas Securities LLC boosted its position in Natera by 1,503.2% during the 3rd quarter. SG Americas Securities LLC now owns 97,973 shares of the medical research company’s stock worth $4,335,000 after acquiring an additional 91,862 shares during the period. Ellsworth Advisors LLC acquired a new stake in Natera during the 3rd quarter worth about $364,000. Finally, Xponance Inc. boosted its position in Natera by 1.8% during the 3rd quarter. Xponance Inc. now owns 14,506 shares of the medical research company’s stock worth $642,000 after acquiring an additional 261 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on NTRA shares. Raymond James lowered Natera from a “strong-buy” rating to an “outperform” rating and lifted their target price for the stock from $68.00 to $85.00 in a report on Tuesday, February 20th. Craig Hallum started coverage on Natera in a report on Monday, April 8th. They set a “buy” rating and a $117.00 target price on the stock. BTIG Research lifted their target price on Natera from $75.00 to $85.00 and gave the stock a “buy” rating in a report on Friday, December 29th. Canaccord Genuity Group lifted their target price on Natera from $87.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, February 29th. Finally, StockNews.com lowered Natera from a “hold” rating to a “sell” rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and a consensus price target of $86.40.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.